A new scoring system in cancer genetics: Application to criteria for BRCA1 and BRCA2 mutation screening

Journal of Medical Genetics

Volumn 51, Issue 2, 2014, Pages 114-121

  Bonaïti, Bernard ^a,b   Alarcon, Flora ^c,d,e   Andrieu, Nadine ^e,f,g   Bonadona, Valérie ^h,i,j   Dondon, Marie Gabrielle ^e,f,g   Pennec, Sophie ^k   Stoppa Lyonnet, Dominique ^d,f,l   Bonaïti Pellié, Catherine ^b,m   Perdry, Hervé ^b,m  

^a UMR1313 GÉNÉTIQUE ANIMALE ET BIOLOGIE INTÉGRATIVE   (France)

^b INSERM   (France)

^c CNRS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e INSERM U900   (France)

^f INSTITUT CURIE   (France)

^g PSL RESEARCH UNIVERSITY   (France)

^h UNIVERSITÉ LYON 1   (France)

ⁱ LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^j CENTRE LÉON BÉRARD   (France)

^k INSTITUT NATIONAL D'ÉTUDES DÉMOGRAPHIQUES   (France)

^l INSTITUT CURIE   (France)

^m UNIVERSITÉ PARIS SACLAY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANCER: BREAST; GENETIC SCREENING/COUNSELLING;

AGE OF ONSET; ALGORITHMS; BREAST NEOPLASMS, MALE; COMPUTER SIMULATION; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HUMANS; MALE; MODELS, GENETIC; MUTATION; PROBABILITY; ROC CURVE;

EID: 84894031472     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmedgenet-2013-101674     Document Type: Article

References (37)

1. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33.
2. Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, Longy M, Guimbaud R, Buecher B, Bignon Y-J, Caron O, Colas C, Noguès C, Lejeune-Dumoulin S, Olivier-Faivre L. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011;305:2304-10.
3. Eisinger F, Bressac B, Castaigne D, Cottu PH, Lansac J, Lefranc JP, Lesur A, Nogues C, Pierret J, Puy-Pernias S, Sobol H, Tardivon A, Tristant H, Villet R. Identification et prise en charge des prédispositions héréditaires aux cancers du sein et de l'ovaire (mise à jour 2004). Bull Cancer 2004;91:219-37.
4. Robson M, Offit K. Management of an inherited predisposition to breast cancer. N Engl J Med 2007;357:154-62.
5. Olschwang S, Bonaiti C, Feingold J, Frebourg T, Grandjouan S, Lasset C, Laurent-Puig P, Lecuru F, Millat B, Sobol H, Thomas G, Eisinger F. Identification et prise en charge du syndrome HNPCC (Hereditary NonPolyposis Colon Cancer), prédisposition héréditaire aux cancers du côlon, du rectum et de l'utérus. Bull Cancer 2004;91:303-15.
6. Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, Lynch P, Burke W, Press N. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006;296:1507-17.
7. Antoniou AC, Easton DF. Risk prediction models for familial breast cancer. Future Oncol 2006;2:257-74.
8. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998;62:145-58.
9. Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 2004;91:1580-90.
10. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;23:111-1130.
11. Evans DG, Eccles DM, Rahman N, Young K, Bulman M, Amir E, Shenton A, Howell A, Lalloo F. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 2004;41:474-80.
12. Evans DG, Lalloo F, Wallace A, Rahman N. Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. J Med Genet 2005;42:e39.
13. Stoppa-Lyonnet D, Noguès C, Sobol H, Eisinger F. Consultations de génétique et prédisposition aux cancers du sein. In Risques héréditaires de cancers du sein et de l'ovaire: Quelle prise en charge? Paris: Inserm, 1998.
14. Bonaïti B, Alarcon F, Bonadona V, et al. Nouveau système de score pour le diagnostic des prédispositions aux cancers du sein et de l'ovaire associées à BRCA1/2. Bull Cancer 2011;98:779-95.
15. Evans DG, Lalloo F, Cramer A, Jones EA, Knox F, Amir E, Howell A. Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 2009;46:811-17.
16. Lakhani SR, Van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-18.
17. Olschwang S. Germline mutation and genome instability. Eur J Cancer Prev 1999;8 (Suppl 1):S33-7.
18. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006;98:1694-706.
19. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HF, Ausems MG, Menko FH, Gomez Garcia EB, Klijn JG, Hogervorst FB, van Houwelingen JC, van't Veer LJ, Rookus MA, van Leeuwen FE. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 2005;42:711-19.
20. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2007;99:1811-14.
21. De Angelis R, Capocaccia R, Hakulinen T, Soderman B, Verdecchia A. Mixture models for cancer survival analysis: application to population-based data with covariates. Stat Med 1999;18:441-54.
22. Bonaiti B, Bonadona V, Perdry H, Andrieu N, Bonaiti-Pellie C. Estimating penetrance from multiple case families with predisposing mutations: extension of the 'genotype-restricted likelihood' (GRL) method. Eur J Hum Genet 2011;19:173-9.
23. Belot A, Grosclaude P, Bossard N, Jougla E, Benhamou E, Delafosse P, Guizard AV, Molinie F, Danzon A, Bara S, Bouvier AM, Tretarre B, Binder-Foucard F, Colonna M, Daubisse L, Hedelin G, Launoy G, Le Stang N, Maynadie M, Monnereau A, Troussard X, Faivre J, Collignon A, Janoray I, Arveux P, Buemi A, Raverdy N, Schvartz C, Bovet M, Cherie-Challine L, Esteve J, Remontet L, Velten M. Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique 2008;56:159-75.
24. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008;26:4282-8.
25. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006;24:5652-7.
26. Antoniou AC, Pharoah PD, McMullan G, Day NE, Stratton MR, Peto J, Ponder BJ, Easton DF. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002;86:76-83.
27. Brozek I, Ochman K, Debniak J, Morzuch L, Ratajska M, Stepnowska M, Stukan M, Emerich J, Limon J. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland. Gynecol Oncol 2008;108:433-7.
28. Jacobi CE, van Ierland Y, van Asperen CJ, Hallensleben E, Devilee P, Jan Fleuren G, Kenter GG. Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort. Genet Med 2007;9:173-9.
29. Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, Smotkin D, Ben-David Y, Rosenblatt J, Russo D, Schwartz P, Tung N, Warner E, Rosen B, Friedman J, Brunet JS, Narod SA. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000;66:1259-72.
30. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-10.
31. Alarcon F, Bourgain C, Gauthier-Villars M, Plante-Bordeneuve V, Stoppa-Lyonnet D, Bonaiti-Pellie C. PEL: an unbiased method for estimating age-dependent genetic disease risk from pedigree data unselected for family history. Genet Epidemiol 2009;33:379-85.
32. Pennec S. Four-Generation families in France. Popul Eng Sel 1997;9:75-101.
33. Toulemon L. How many children and how many siblings in France in the last century? Popul Societies 2001;373:1-4.
34. Elston RC, Stewart J. A general model for the genetic analysis of pedigree data. Hum Hered 1971;21:523-42.
35. Bonaiti-Pellie C, Andrieu N, Arveux P, Bonadona V, Buecher B, Delpech M, Jolly D, Julian-Reynier C, Luporsi E, Nogues C, Nowak F, Olschwang S, Orsi F, Pujol P, Saurin JC, Sinilnikova O, Stoppa-Lyonnet D, Thepot F. Oncogénétique: estimation des besoins de la populations en France pour les 10 ans à venir. Bull Cancer 2009;96:875-900.
36. Antoniou AC, Hardy R, Walker L, Evans DG, Shenton A, Eeles R, Shanley S, Pichert G, Izatt L, Rose S, Douglas F, Eccles D, Morrison PJ, Scott J, Zimmern RL, Easton DF, Pharoah PD. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 2008;45:425-31.
37. Cui J, Hopper JL. Why are the majority of hereditary cases of early-onset breast cancer sporadic? A simulation study. Cancer Epidemiol Biomarkers Prev 2000;9:805-12.